Sage shrinks workforce by 40% in light of major depression drug rejection
Sage Therapeutics is laying off 40% of its workforce this quarter in the wake of the FDA’s rejection of the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
